Pegylated Interferon Beta-1a for Multiple Sclerosis

%jwplayer%

The MD Magazine Peer Exchange "Modifying the Course of Multiple Sclerosis in New Ways: The Latest Advances in Treatment" features a distinguished panel of physician experts discussing key topics in multiple sclerosis (MS) research and management, including the latest insights into MS pathophysiology, new medication options and their application in clinical practice, and more.

Services at Ursinus College, in Collegeville, PA.

The panelists are:

• Fred D. Lublin, MD, FAAN, FANA, the Saunders Family Professor of Neurology and director of The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, and co-chief editor of Multiple Sclerosis and Related Disorders at the Icahn School of Medicine at Mount Sinai
• Patricia K. Coyle, MD, professor of neurology, vice chair of Clinical Affairs, and director of MS Comprehensive Care Center
• Suhayl Dhib-Jalbut, MD, professor and chief of the Department of Neurology at Rutgers, Robert Wood Johnson Medical School

to be well tolerated several years into therapy, with a very low rate of neutralizing antibodies and a low drop-out rate.

Coyle still has questions about whether or not to select pegylated interferon beta-1a for patients with significant preexisting headache, spasticity, or depression.

Just to clarify the terminology, Lublin enumerated the brand names for the new MS therapies: the pegylated interferon beta-1a is Plegridy, fingolimod is Gilenya, teriflunomide is Aubagio, dimethyl fumarate is Tecfidera, and alemtuzumab is also called Lemtrada.